{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:44:20Z","timestamp":1782726260728,"version":"3.54.5"},"reference-count":79,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2026.2694387","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:42:15Z","timestamp":1782218535000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF"],"prefix":"10.1080","volume":"25","author":[{"given":"Naruhiko","family":"Ishiwada","sequence":"first","affiliation":[{"name":"Chiba University","place":["Chiba City, Chiba Prefecture, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi K.K. Market Access","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Arashiro","sequence":"additional","affiliation":[{"name":"Sanofi K.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Reygrobellet","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Yarnoff","sequence":"additional","affiliation":[{"name":"Evidera Inc","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Musci","sequence":"additional","affiliation":[{"name":"Evidera Inc","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Ghemmouri","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1062726"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91502"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.06.003"},{"issue":"5","key":"e_1_3_6_5_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jpids\/piz087","article-title":"Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States, 2014\u201315","volume":"9","author":"Arriola CS","year":"2020","unstructured":"Arriola CS, Kim L, Langley G, et al. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States, 2014\u201315. J Pediatr Infect Dis Soc. 2020;9(5):587\u2013595.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"2","key":"e_1_3_6_6_1","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall CB","year":"2013","unstructured":"Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341\u2013348.","journal-title":"Pediatrics"},{"issue":"2","key":"e_1_3_6_7_1","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","article-title":"Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model","volume":"226","author":"Kieffer A","year":"2022","unstructured":"Kieffer A, Beuvelet M, Sardesai A, et al. Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis. 2022;226(Suppl 2):S282\u2013s292.","journal-title":"J Infect Dis"},{"issue":"11","key":"e_1_3_6_8_1","doi-asserted-by":"crossref","first-page":"e70045","DOI":"10.1111\/irv.70045","article-title":"Inpatient burden of respiratory syncytial virus infection and Influenza in children younger than 5 years in Japan, 2011\u20132022: a database study","volume":"18","author":"Arashiro T","year":"2024","unstructured":"Arashiro T, Kramer R, Jin J, et al. Inpatient burden of respiratory syncytial virus infection and Influenza in children younger than 5 years in Japan, 2011\u20132022: a database study. Influenza Other Respir Viruses. 2024;18(11):e70045.","journal-title":"Influenza Other Respir Viruses"},{"key":"e_1_3_6_9_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Review report. 2013."},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.12.017"},{"key":"e_1_3_6_11_1","unstructured":"Japan Pediatric Society. Consensus guidelines for the use of nirsevimab in Japan. 2025."},{"key":"e_1_3_6_12_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Review report: abrysvo (respiratory syncytial virus vaccine). Pharmaceuticals and Medical Devices Agency; 2024."},{"key":"e_1_3_6_13_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Approval of abrysvo (respiratory syncytial virus vaccine). Pharmaceuticals and Medical Devices Agency; 2024."},{"issue":"1","key":"e_1_3_6_14_1","first-page":"59","article-title":"Breast milk prefusion F immunoglobulin G as a correlate of protection against respiratory syncytial virus acute respiratory illness","volume":"219","author":"Mazur NI","year":"2019","unstructured":"Mazur NI, Horsley NM, Englund JA, et al. Breast milk prefusion F immunoglobulin G as a correlate of protection against respiratory syncytial virus acute respiratory illness. J Infect Dis. 2019;219(1):59\u201367.","journal-title":"J Infect Dis"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003854"},{"key":"e_1_3_6_16_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). Guidelines for RSV prevention and national immunization planning. 2026."},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01134-1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2112186"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110275"},{"key":"e_1_3_6_21_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council. National Institute of Public Health (C2H); 2024."},{"key":"e_1_3_6_22_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Synagis package insert. Version 3. 2024."},{"key":"e_1_3_6_23_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). Vital statistics. 2022."},{"key":"e_1_3_6_24_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). Demographic survey ministry of health labour and welfare. 2022."},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14957"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00454-2"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.3.531"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011491"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1812OC"},{"key":"e_1_3_6_30_1","unstructured":"Japan Institute for Health Security. IDWR surveillance data. 2024."},{"key":"e_1_3_6_31_1","unstructured":"Japan Institute for Health Security NIoID. Infectious diseases weekly report Japan \u2014 issue: 2026 week 6 (2 Feb\u20138 Feb 2026). Infectious disease weekly report (IDWR) vol. 28 no. 6. Ministry of Health Labour and Welfare; 2026."},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00321-2"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(25)00102-6"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.29.2001600"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00742-X"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02316-5"},{"key":"e_1_3_6_37_1","unstructured":"Vaccines and Related Biological Products Advisory Committee Meeting. FDA briefing document. Respiratory syncytial virus vaccine (proposed trade name: abrysvo). 2023 [cited 2023]. Available from: https:\/\/www.fda.gov\/media\/168185\/download"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005816"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.023"},{"key":"e_1_3_6_40_1","unstructured":"UK Health Security Agency. Respiratory syncytial virus: the green book chapter 27a. 2015."},{"key":"e_1_3_6_41_1","unstructured":"Wilson M Whitaker H Walker J et al. Maternal RSV vaccination and reduced risk of hospitalisation for babies in England 2024\/25. UK Health Security Agency ESCMID Global; 2025."},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01000-6"},{"key":"e_1_3_6_43_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). Number of people receiving routine vaccinations (FY1995 \u2013 FY2021). 2026."},{"key":"e_1_3_6_44_1","unstructured":"World Health Organization. Japan: WHO and UNICEF estimates of immunization coverage: 2023 revision. 2024."},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2025.102892"},{"key":"e_1_3_6_46_1","unstructured":"Kanehisa Laboratories. KEGG drug entry: nirsevimab (D11380). KEGG Database; 2026."},{"key":"e_1_3_6_47_1","unstructured":"Okayama Prefecture. Notification on vaccination costs for FY 2026 (including recombinant RSV vaccine for pregnant women). Okayama (JP): Okayama Prefectural Government; 2026."},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-023-00708-w"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2023-0069"},{"key":"e_1_3_6_50_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). Medical fee list."},{"key":"e_1_3_6_51_1","unstructured":"Environmental Restoration and Conservation Agency. Research on the long-term course and prognosis of bronchial asthma patients by age group. 2005."},{"key":"e_1_3_6_52_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). Vaccination basic policy subcommittee. Committee report."},{"key":"e_1_3_6_53_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). Basic survey on wage structure. 2021."},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-066461"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2591816"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127191"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004936"},{"key":"e_1_3_6_58_1","unstructured":"Ministry of Health Labour and Welfare (MHLW). 72nd meeting of the basic policy subcommittee on immunization immunization and vaccines health science council. 2025."},{"key":"e_1_3_6_59_1","unstructured":"US Advisory Committee on Immunization Practices (ACIP). ACIP evidence to recommendations for use of nirsevimab in infants born during the RSV season or entering their first RSV season. Prevention UCfDCa; 2024."},{"key":"e_1_3_6_60_1","unstructured":"US Advisory Committee on Immunization Practices (ACIP). ACIP evidence to recommendations for use of nirsevimab in children 8\u201319 months of age at increased risk of severe disease entering their second RSV season. Prevention UCfDCa; 2024."},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2024.5572"},{"issue":"37","key":"e_1_3_6_62_1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.15585\/mmwr.mm7437a1","article-title":"Nirsevimab effectiveness against intensive care unit admission for respiratory syncytial virus in infants - 24 states, December 2024-April 2025","volume":"74","author":"Zambrano LD","year":"2025","unstructured":"Zambrano LD, Simeone RM, Newhams MM, et al. Nirsevimab effectiveness against intensive care unit admission for respiratory syncytial virus in infants - 24 states, December 2024-April 2025. MMWR Morb Mortal Wkly Rep. 2025;74(37):580\u2013588.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127716"},{"issue":"21","key":"e_1_3_6_64_1","article-title":"Lessons from implementing a long-acting monoclonal antibody (nirsevimab) for RSV in France, Spain and the US","volume":"4","author":"Morris T","year":"2025","unstructured":"Morris T, Acevedo K, Alde\u00e1n JA, et al. Lessons from implementing a long-acting monoclonal antibody (nirsevimab) for RSV in France, Spain and the US. Discover Health Syst. 2025;4(21):1\u20137.","journal-title":"Discover Health Syst"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00233-6"},{"key":"e_1_3_6_66_1","unstructured":"Health Protection Surveillance Centre. Technical report: RSV immunisation pathfinder programme 1.0 evaluation. Dublin (IE): Health Protection Surveillance Centre; 2025."},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24082"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908380"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216480"},{"issue":"39","key":"e_1_3_6_70_1","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.15585\/mmwr.mm6939a2","article-title":"Influenza and tdap vaccination coverage among pregnant women - United States, April 2020","volume":"69","author":"Razzaghi H","year":"2020","unstructured":"Razzaghi H, Kahn KE, Black CL, et al. Influenza and tdap vaccination coverage among pregnant women - United States, April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(39):1391\u20131397.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"38","key":"e_1_3_6_71_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.15585\/mmwr.mm7338a2","article-title":"Maternal respiratory syncytial virus vaccination and receipt of respiratory syncytial virus antibody (nirsevimab) by infants aged <8 months - United States, April 2024","volume":"73","author":"Razzaghi H","year":"2024","unstructured":"Razzaghi H, Garacci E, Kahn KE, et al. Maternal respiratory syncytial virus vaccination and receipt of respiratory syncytial virus antibody (nirsevimab) by infants aged <8 months - United States, April 2024. MMWR Morb Mortal Wkly Rep. 2024;73(38):837\u2013843.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_6_72_1","unstructured":"Ponencia de Programa y Registro de Vacunaciones. Recommendations for passive immunization to prevent severe RSV disease in the pediatric population. Ministerio de Sanidad; 2024."},{"key":"e_1_3_6_73_1","unstructured":"Corremans A Dehaene I Lewi L et al. VVOG\/CRGOLFB position regarding maternal vaccination against RSV season 2025\u20132026. VVOG; 2025."},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01194-3"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-026-01372-5"},{"key":"e_1_3_6_76_1","doi-asserted-by":"crossref","unstructured":"Hoshi SL Seposo X Kondo M. Economic impact of RSV prefusion F protein-based (RSVpreF) vaccination and nirsevimab prophylaxis on RSV-associated disease among Japanese infants. Value Health. 2026.","DOI":"10.1016\/j.jval.2026.01.010"},{"key":"e_1_3_6_77_1","doi-asserted-by":"crossref","unstructured":"Monoi A Endo A Kriznar M et al. Optimal seasonal timing of infant immunization to prevent RSV hospitalizations in Japan: a modelling study. medRxiv. 2026.","DOI":"10.64898\/2026.02.14.26346252"},{"key":"e_1_3_6_78_1","unstructured":"UK Health Security Agency. Respiratory syncytial virus (RSV) maternal vaccination coverage in England: August 2025. 2026."},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128566"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00570-X"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2694387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14760584.2026.2694387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2694387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:52:01Z","timestamp":1782723121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2026.2694387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2026.2694387"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2026.2694387","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2694387"}}